Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI

Neurology

Volumn 86, Issue 15, 2016, Pages 1377-1385

  Landau, Susan M ^a,b   Horng, Andy ^a   Fero, Allison ^b   Jagust, William J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; FLORBETAPIR F 18; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; AMYGDALA; ARTICLE; BRAIN ATROPHY; BRAIN STEM; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE AGING; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL NEUROIMAGING; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPERTENSION; IMAGE ANALYSIS; MALE; MEDIAL TEMPORAL LOBE; MEDICAL HISTORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RADIOLOGICAL PARAMETERS; REY AUDITORY VERBAL LEARNING TEST; SCORING SYSTEM; WHITE MATTER; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; LONGITUDINAL STUDY; METABOLISM; MULTICENTER STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITIVE DYSFUNCTION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 84964896939     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002576     Document Type: Article

References (39)

1. Fleisher AS, Chen K, Liu X, et al. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013;34:1-12.
2. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9:S72-S83.
3. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimers disease. N Engl J Med 2014;370:322-333.
4. Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimers disease patients. Alzheimers Dement 2016;12: 110-120.
5. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
6. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid- beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012; 79:1636-1644.
7. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015;313:1939-1949.
8. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimers disease: Alzheimers Disease Centers Consortium on Apolipoprotein E and Alzheimers Disease. N Engl J Med 1998;338:506-511.
9. Monsell SE, Kukull WA, Roher AE, et al. Characterizing apolipoprotein E epsilon4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal beta-amyloid peptide plaques. JAMA Neurol 2015;72:1124-1131.
10. Cairns NJ, Perrin RJ, Franklin EE, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology 2015;35: 390-400.
11. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimers Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201-209.
12. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70-77.
13. Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol 2012;69:623-629.
14. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated betaamyloid deposition in elderly subjects. Brain 2009;132: 1310-1323.
15. Landau SM, Jagust WJ. AV45 Analysis Methods (Version: 2015-12-03). Available at: ida.loni.usc.edu/pages/access/studyData.jsp. Accessed March 4, 2016.
16. Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimers disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 2014;41: 1398-1407.
17. Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56:567-574.
18. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32: 1207-1218.
19. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimers Disease Neuroimaging Initiative subjects. Ann Neurol 2009; 65:403-413.
20. Vemuri P, Senjem ML, Gunter JL, et al. Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimers disease. Neuroimage 2015; 113:61-69.
21. Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fullyautomated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging 2009;21:239-251.
22. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
23. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
24. Rey A. lExamen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.
25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimers disease. Am J Psychiatry 1984;141: 1356-1364.
26. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression rating scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
27. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95-113.
28. Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009;66:1557-1562.
29. Rosen RF, Ciliax BJ, Wingo TS, et al. Deficient highaffinity binding of Pittsburgh compound B in a case of Alzheimers disease. Acta Neuropathol 2010;119: 221-233.
30. Beach TG, Schneider JA, Sue LI, et al. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of Alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol 2014;73:948-953.
31. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir2 PET for imaging beta-amyloid pathology. JAMA 2011;305:275-283.
32. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74: 826-836.
33. Thal DR, Beach TG, Zanette M, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimers disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 2015;11:975-985.
34. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012;69:493-498.
35. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF III. Late-life depression and risk of vascular dementia and Alzheimers disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013;202:329-335.
36. Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimers disease in 30 US Alzheimers disease centers. J Alzheimers Dis 2012;31: 265-275.
37. Franklin EE, Perrin RJ, Vincent B, et al. Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimers Disease Neuroimaging Initiative 2 participants. Alzheimers Dement 2015;11:815-822.
38. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005;76:1485-1490.
39. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234.